The BBB’s threat to biosimilar drug development


23 November 2021 - In 2019, longtime pharmaceutical industry critic, Peter Bach, took to the Wall Street Journal to declare that the U.S. should throw in the towel on copycat versions of the nation’s highest priced specialty drugs in favour of government price controls. 

The recommendation was rightly maligned by those who recognise the undeniable role drug competition plays in driving down medicine costs for patients and taxpayers, alike.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Biosimilar , Development